---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic burden and healthcare resource utilization. Topics: U.S. commercial and Medicaid claims (2002 to 2009): direct medical costs by stage; U.S. Medicare fee-for-service claims (2013 to 2017): costs versus matched beneficiaries and by stage; U.S. Medicaid Analytic eXtract (2010 to 2014): costs versus matched beneficiaries and by stage; U.S. MarketScan commercial, Medicaid, and Medicare Supplemental claims (2009 to 2018): HRU and costs per patient per month by stage; 24 further topics. 28 evidence topics quoted from 30 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### U.S. commercial and Medicaid claims (2002 to 2009): direct medical costs by stage

> “Among 1272 HD patients, the mean age was similar in commercial (752 patients) and Medicaid (520 patients) populations”
> “The mean total annualized cost per patient increased by stage (commercial: $4947 (SD = $6040)-$22,582 (SD = $39,028); Medicaid: $3257 (SD = $5670)-$37,495 (SD = $27,111).”
> “The vast majority (73.8%) of Medicaid Late stage patients received nursing home care and the majority (54.6%) of Medicaid Late stage costs were associated with nursing home care.”
> “Key limitations include the classification of patients into a single stage, as well as a lack of visibility into full long-term care/nursing home-related costs for commercial patients.”

Source: [Divino et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23789925/)

<a id="topic-2.2.1.8.2-2"></a>

### U.S. Medicare fee-for-service claims (2013 to 2017): costs versus matched beneficiaries and by stage

> “We identified 3,688 matched pairs of beneficiaries with and without HD.”
> “Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001).”
> “In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).”

Source: [Exuzides et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34730477/)

<a id="topic-2.2.1.8.2-3"></a>

### U.S. Medicaid Analytic eXtract (2010 to 2014): costs versus matched beneficiaries and by stage

> “A total of 1,785 beneficiaries without HD were matched to 595 beneficiaries with HD (139 early-, 78 middle-, and 378 late-stage).”
> “The mean (SD) annual total costs were higher for beneficiaries with HD than beneficiaries without HD ($73,087 [$75,140] vs. $26,834 [$47,659], p <.001) and driven by inpatient costs ($45,190 [$48,185] vs. $13,808 [$39,596], p <.001).”
> “Total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $22,797 [$31,683] for early-stage HD vs. $55,294 [$129,290] for middle-stage HD vs. $95,251 [$60,197] for late-stage HD; p <.001).”

Source: [Patel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285853/)

<a id="topic-2.2.1.8.2-4"></a>

### U.S. MarketScan commercial, Medicaid, and Medicare Supplemental claims (2009 to 2018): HRU and costs per patient per month by stage

> “A total of 2,669 individuals with HD were identified. Of these, 1,432 (53.7%), 689 (25.8%), and 548 (20.5%) had early-, middle-, and late-stage HD at baseline, respectively.”
> “Mean total all-cause healthcare cost PPPM for individuals with HD was $2,889, and it was significantly higher in middle-stage individuals, at $7,988, compared with early- and late-stage individuals, at $3,726 and $5,125, respectively; p <0.0001.”
> “Our evaluations didn't include the indirect costs of HD, which may be substantial as HD typically affects people at their peak earning potential.”

Source: [Exuzides et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/35608039/)

<a id="topic-2.2.1.8.2-5"></a>

### U.S. MarketScan claims: costs versus propensity-matched controls without HD

> “A total of 2,473 individuals with HD and 9,522 matched non-HD controls were identified.”
> “Mean total costs (2018 USD PPPM) for the HD cohort ($2,260 [SD = $4,682]) were twice the total costs in the non-HD cohort ($1,056 [SD = $3,078]) (P < 0.0001) and were highest across all disease stages.”

Source: [To et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373050/)

<a id="topic-2.2.1.8.2-6"></a>

### U.S. MarketScan claims: late-onset versus adult-onset HD

> “In total, 763 individuals with LoHD and 1,073 individuals with AoHD were matched with 3,762 non-HD controls.”
> “In the 12 months post-index, mean total costs for the LoHD cohort ($29,055) were significantly higher than for non-HD controls (≥60 years old: $17,286; 21-59 years old: $12,688; p <.001) and similar to total costs in the AoHD cohort ($31,701; p =.47).”

Source: [To et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37350423/)

<a id="topic-2.2.1.8.2-7"></a>

### U.S. MarketScan claims (2017 to 2021): HD-related costs by diagnosing provider type

> “Three hundred and forty eligible patients had a mean age at diagnosis of 49 years.”
> “HD-related mean costs totaled $2,489 ($1,179 inpatient and $1,310 outpatient).”
> “Patients diagnosed by neurologists had significantly lower HD-related total non-medication costs vs. those diagnosed by PCPs (-$2,256; p < 0.05).”

Source: [Kim et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39373538/)

<a id="topic-2.2.1.8.2-8"></a>

### Systematic review of cost-of-illness studies: annual costs by stage and cost type (2023 U.S. dollars)

| Cost type and study | “Early” | “Middle” | “Late” |
| --- | --- | --- | --- |
| Inpatient, Divino | “1150” | “5045” | “9216” |
| Inpatient, Exuzides | “1225” | “4250” | “22,228” |
| Inpatient, Patel | “791” | “3,070” | “65,465” |
| Outpatient, Divino | “2956” | “10,508” | “30,104” |
| Outpatient, Exuzides | “4736” | “10,361” | “13,665” |
| Outpatient, Patel | “5676” | “11639” | “6226” |
| Drug, Divino | “2483” | “4518” | “4838” |
| Drug, Exuzides | “15,663” | “16,790” | “23,944” |
| Drug, Patel | “6330” | “14149” | “13,108” |
| Caregiving, Jones | “6073” | “44,662” | “133,200” |
| Caregiving, Silva-Pardes | “6041” | “16,502” | “21,438” |

Source: [Patil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11717757/)

<a id="topic-2.2.1.8.2-9"></a>

### Systematic review of cost-of-illness studies: synthesis

> “Only five studies were included for extraction and synthesis including three from the USA, one from the United Kingdom (UK), and one from Peru.”
> “Outpatient costs were approximately 2.5 times greater than inpatient costs for early and middle stages of HD.”
> “Among all the costs associated with HD, annual caregiver cost emerges as the most significant costs in the economic burden of HD, ranging from a minimum of $6041 for early stage to a maximum of $133,200 for late-stage HD.”

Source: [Patil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11717757/)

<a id="topic-2.2.1.8.2-10"></a>

### Global systematic review: annual costs by region (2024 U.S. dollars)

> “Out of the initial 608 de-duplicated articles, 19 full-text articles were included.”
> “Annual costs in 2024 USD ranged significantly by region: Americas ($2542-$90,515), Europe ($40,000-$215,020), Asia ($1915-$7132), and Oceania ($3678-$8721).”

Source: [Gokhale and Villa Zapata (2025)](https://pubmed.ncbi.nlm.nih.gov/39973389/)

<a id="topic-2.2.1.8.2-11"></a>

### HDBOI study (France, Germany, Italy, Spain, United Kingdom, United States): direct, nondirect, and indirect costs

> “HDBOI cost estimates were €12,663 (n = 2094) for direct medical costs, €2984 (n = 359) for nondirect medical costs, and €47,576 (n = 436) for indirect costs.”
> “Costs are higher in patients who are at later stages of disease; for example, direct medical costs estimates were €9220 (n = 846), €11,885 (n = 701), and €18,985 (n = 547) for ES, MS, and AS, respectively.”
> “Costs show large variations between patients and countries.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-12"></a>

### HDBOI study: design, participants, and costing methods

> “The HDBOI study is a noninterventional, retrospective, cross-sectional, international burden of illness study of people with diagnosed HD in France, Germany, Italy, Spain, the UK, and the USA.”
> “A total of 2094 PwHD were enrolled in the HDBOI study, 40% of whom (n = 846) were classified as ES, 34% as MS (n = 701), and 26% as AS (n = 547; Table 1).”
> “Information regarding HD-related health care resource use used to compute direct medical costs was available for all 2094 PwHD. Information on direct nonmedical costs was available for 359 PwHD and indirect costs for 436 PwHD.”
> “Costs are reported in 2020 euros for all outcomes”
> “To minimize underestimation of costs due to potentially reduced care interactions during the coronavirus disease 2019 (COVID-19) pandemic, health care resource use (used to compute direct medical costs) was extracted for a set time period before the pandemic (March 2019 through March 2020).”
> “For actively employed PwHD and caregivers, productivity loss was quantified as the number of days missed from work due to HD in the past 3 months multiplied by the country average salary per day.”
> “For those unable to work due to HD, an opportunity cost was assigned based on 1 year of average salary per country.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-13"></a>

### HDBOI study: mean annual costs by disease stage (2020 euros)

| Cost category | Total, mean (SD) | Early stage, mean (SD) | Mid stage, mean (SD) | Advanced stage, mean (SD) |
| --- | --- | --- | --- | --- |
| Direct medical costs | “€12,663 (€34,012)” | “€9220 (€31,855)” | “€11,885 (€31,827)” | “€18,985 (€38,811)” |
| Direct nonmedical costs | “€2984 (€3627)” | “€2275 (€3530)” | “€2956 (€3632)” | “€4180 (€3500)” |
| Indirect costs | “€47,576 (€47,985)” | “€35,859 (€44,874)” | “€51,996 (€45,549)” | “€56,947 (€51,723)” |
| Total costs | “€62,372 (€51,197)” | “€42,477 (€45,651)” | “€64,688 (€53,698)” | “€86,177 (€44,966)” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-14"></a>

### HDBOI study: cost drivers and mean annual cost components by stage (2020 euros)

> “Inpatient hospitalizations and residential care were the primary drivers of direct medical costs”
> “Total costs (sum of direct medical, nonmedical, and indirect costs), available for a subsample of 307 PwHD (patients with a completed eCRF, PPIE-P, and PPIE-C), were driven primarily by indirect costs, which accounted for 84%, 80%, and 66% of ES, MS, and AS total costs, respectively (Appendix Table A2).”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

| Cost component | Early stage, mean (SD) and n | Mid stage, mean (SD) and n | Advanced stage, mean (SD) and n |
| --- | --- | --- | --- |
| Consultations | “€727 (€1216) n = 829” | “€767 (€975) n = 693” | “€1051 (€1335) n = 545” |
| Hospital inpatient | “€35,803 (€102,653) n = 28” | “€30,698 (€39,581) n = 23” | “€12,658 (€42,550) n = 60” |
| Treatment | “€6333 (€25,525) n = 667” | “€6539 (€28,257) n = 571” | “€7922 (€26,248) n = 454” |
| Residential care | “€41,879 (€46,946) n = 16” | “€56,673 (€40,806) n = 26” | “€45,977 (€31,915) n = 98” |
| Professional caregiver | “€1286 (€4355) n = 204” | “€2308 (€9831) n = 164” | “€2582 (€8632) n = 114” |
| State support, patient | “€841 (€2123) n = 204” | “€1199 (€2497) n = 164” | “€2677 (€3437) n = 114” |
| Lost productivity, PwHD | “€23,216 (€16,848) n = 75” | “€31,824 (€13,934) n = 109” | “€34,343 (€10,295) n = 98” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-15"></a>

### HDBOI study: mean annual costs by country (2020 euros)

> “Direct nonmedical costs were highest in Italy (€3977) and the UK, and indirect costs were highest in the USA (€74,228 [$90,187]), the UK, and Italy”
> “The HDBOI study reported direct medical costs of €27,743 in the USA and a substantial indirect cost burden of €74,228 from lost work productivity.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

| Country | Direct medical costs | Indirect costs |
| --- | --- | --- |
| France | “4167” | “39471” |
| Germany | “11560” | “39451” |
| Italy | “6934” | “47048” |
| Spain | “5814” | “43547” |
| United Kingdom | “12606” | “52472” |
| United States | “27743” | “74228” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-16"></a>

### HDBOI study: stated limitations of the cost estimates

> “Because recruitment was driven through clinician office visits, AS patients may have been underrepresented if they were admitted to long-term residential or nursing care homes.”
> “Cost estimates for AS PwHD may have been underestimated due to the small sample of patients with advanced disease and subsequent subgroup analyses.”
> “For Germany, direct medical costs may have been underestimated, as only copayments were publicly available, which do not reflect the true cost of the service delivered.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-17"></a>

### United Kingdom EHDN REGISTRY: annual societal costs by TFC stage (2013 pounds)

| Category | “Stage I: TFC 11–13 (n = 43)” | “Stage II: TFC 7–10 (n = 37)” | “Stage III: TFC 3–6 (n = 38)” | “Stage IV: TFC 1–2 (n = 13)” | “All stages (n = 131)” |
| --- | --- | --- | --- | --- | --- |
| Informal care, mean | “£1073.86” | “£4941.41” | “£21 051.79” | “£62 784.00” | “£14 085.24” |
| Total, mean | “£2250.06” | “£11 867.76” | “£29 671.91” | “£89 759.62” | “£21 605.08” |

Source: [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)

<a id="topic-2.2.1.8.2-18"></a>

### United Kingdom EHDN REGISTRY: cost drivers

> “The mean annual cost per person with HD was £21 605. The largest proportion of this cost (65%) was due to informal care (£14 085).”
> “This equates to £195 million per year in the UK.”

Source: [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)

<a id="topic-2.2.1.8.2-19"></a>

### Norway: six-month healthcare and societal costs

> “Total six-month healthcare costs and total societal costs were € 18,538 and € 66,789 respectively.”
> “Main six-month cost components for the three disease phases were informal care costs (€ 30,605) accounting for approximately half the total societal costs, and costs due to production loss (€ 18,907) being slightly higher than the total healthcare costs.”

Source: [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)

<a id="topic-2.2.1.8.2-20"></a>

### Long-term care in advanced HD: North American systematic literature review

> “Most patients with advanced HD receive LTC in a nursing home (35%) or at home (32%), with fewer patients receiving LTC from hospitals, hospices, and multi-setting facilities”
> “A long period of time is spent in both nursing home and hospice care, leading to sizeable annual costs for this care provision.”

Source: [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)

<a id="topic-2.2.1.8.2-21"></a>

### Hospice and palliative care utilization in the United States

> “Of the 164,032 patients admitted to these hospices, 101 (0.06%) had a primary diagnosis of HD.”
> “Patients had a median length of stay in hospice of 42 days, which was significantly longer than that of other hospice patients in the sample (17 days), P < 0.001.”

Source: [Johnson et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916295/)

> “8521 patients with HD were admitted to the hospital. Of those, 321 (3.8%) received specialty PC.”

Source: [Sokol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9436638/)

<a id="topic-2.2.1.8.2-22"></a>

### Predictors of health care utilization: Enroll-HD Northern America

> “Visits from 1,631 participants in the Northern America region from the Enroll-HD study were included in this study.”
> “Clinical factors, such as psychiatric symptoms, functional ability, and comorbidities, were associated with use of multiple types of health care services.”

Source: [Ogilvie et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12021023/)

<a id="topic-2.2.1.8.2-23"></a>

### Employment loss by disease stage: Enroll-HD

> “At baseline visit, 47.5% of patients with TFC score 11–13 (n=2,512) were unemployed; 19.9% of them due to illness and 15.4% were on sick leave.”
> “89.8% of patients with TFC score 7–10 (n=2,794) were unemployed; 37.8% of them due to illness and 19.7% were on sick leave.”
> “By 4 years post-clinical diagnosis, <20% patients stayed employed.”

Source: [Ko et al. (2020)](https://www.mdsabstracts.org/abstract/burden-of-huntingtons-disease-hd-on-loss-of-employment-status-and-its-association-with-disease-stage/)

<a id="topic-2.2.1.8.2-24"></a>

### Employment and work productivity: HDBOI participants

> “Approximately 27% of the PPIE-P sample reported stopping work early (i.e., retiring) due to HD.”
> “Of those who reported being employed for pay overall work productivity loss increased with disease severity: 43% in ES, 55% in MS, and 57% in AS.”

Source: [Rodríguez-Santana et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-patient-poster-final-version-pdf.pdf)

<a id="topic-2.2.1.8.2-25"></a>

### Employment: chorea and cognitive decline

> “Patients with chorea were less likely to be employed full-time (16.7% vs 25.7%; P<0.04) and more likely to be on long-term sick leave (17.4% vs 5.0%; P<0.01).”

Source: [Claassen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8216765/)

> “For every year delay in cognitive symptom onset, there was a 0.806 year increase in age at leaving work (SE = 0.030, p < 0.001, adj-R2 = 0.628).”

Source: [Watkins et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30198875/)

> “Twenty-three studies were identified and showed that while employment and working capacity in HD are negatively influenced by cognitive decline and motor impairments, apathy already plays a role in the prodromal stage.”

Source: [van der Zwaan et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35379551/)

<a id="topic-2.2.1.8.2-26"></a>

### Canada (Alberta): direct healthcare costs under a universal public system

> “The mean total all-cause direct healthcare costs were $23,211 [$38,599] per person-year, with hospitalizations accounting for 57.8% of all-cause costs.”
> “Costs were higher among individuals with a long-term care stay, a proxy for disease severity.”

Source: [Shaw et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/35073826/)

<a id="topic-2.2.1.8.2-27"></a>

### Other countries: Israel, China, Peru, Brazil, and Germany

> “Total healthcare and medication costs per patient (US dollars) were significantly higher for PwHD than controls ($7,343 vs. $3,625; P < 0.001).”

Source: [Barer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10366633/)

> “The average annual direct medical cost, direct non-medical cost, and indirect cost were 3,265.65, 805.82, and 801.97 Euros, respectively.”

Source: [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38142687/)

> “The average annual cost of HD reached USD 8120 per patient in 2015.”
> “The mean cost of HD increased with the degree of patient dependency: from USD 6572 for Barthel 4 & 5 (slight dependency and total independency, respectively) to USD 23,251 for Barthel 1 (total dependency).”

Source: [Silva-Paredes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6937635/)

> “Significant economic impacts were observed, with average annual direct medical costs of $4686.82 per HD patient.”
> “Thirty-three out of 34 HD patients were unemployed or retired, and 16 relied on government benefits, reflecting broader socioeconomic implications.”

Source: [da Silva van der Laan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39150831/)

> “Physical therapy was the most often used medical aid in HD patients (46.4%). Nursing services and speech therapy were used by 27.9 and 22.7% of HD patients, respectively, whereas use of psychotherapy was rare (3.2%).”

Source: [Ohlmeier et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6905058/)

<a id="topic-2.2.1.8.2-28"></a>

### U.S. indirect and out-of-pocket costs: HD-Charge survey

> “The indirect and out-of-pocket costs of HD in the US have not been quantified.”
> “Quantify out-of-pocket expenses for HDGECs and companions”

Source: [ClinicalTrials.gov NCT03628235](https://clinicaltrials.gov/study/NCT03628235)

Additional sources: [Ekkel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37269816/); [Winder et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30103341/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
